Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 6/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.60 |
| ▸ | MEN1 | O00255 | 4/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 4/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.59 |
| ▸ | STS | P08842 | 4/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.58 |
| ▸ | TP53 | P04637 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | CA1 | P00915 | 2/20 | 0.58 |
| ▸ | CA2 | P00918 | 2/20 | 0.58 |
| ▸ | CA9 | Q16790 | 2/20 | 0.58 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Promestriene SCHEMBL5188890 | 1.00 | ESR1 (0.61) | ESR1MAPTKMT2AMEN1THRB | |
| Promestriene SCHEMBL31613772 | 1.00 | ESR1 (0.61) | ESR1MAPTKMT2AMEN1THRB | |
| SCHEMBL18738857 | 0.92 | MAPT (0.60) | ESR1MAPTKMT2AMEN1THRB | |
| Promestriene SCHEMBL16174486 | 0.89 | ESR1 (0.65) | ESR1MAPTKMT2AMEN1LMNA | |
| SCHEMBL13951927 | 0.89 | MAPT (0.61) | ESR1MAPTKMT2AMEN1THRB | |
| SCHEMBL19961981 | 0.87 | ESR1 (0.77) | ESR1MAPTKMT2AMEN1THRB | |
| SCHEMBL11303367 | 0.87 | ESR1 (0.77) | ESR1MAPTKMT2AMEN1THRB | |
| SCHEMBL6856667 | 0.87 | ESR1 (0.77) | ESR1MAPTKMT2AMEN1THRB | |
| SCHEMBL18687578 | 0.87 | HSD17B10 (0.75) | ESR1MAPTKMT2AMEN1LMNA | |
| SCHEMBL28503910 | 0.87 | HSD17B10 (0.75) | ESR1MAPTKMT2AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 381 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250255968-A1 | INTRAVAGINAL DEVICES FOR DRUG DELIVERY | KISER PATRICK F (US) | 2025-08-14 | — | — | US | claimed |
| EP-4101437-B1 | BACTERIOSTATIC COMPOSITION, PREPARATION METHOD THEREFOR AND USE THEREOF | SHENZHEN EULIKAN BIOTECHNOLOGY CO LTD (CN) | 2025-06-11 | — | — | EP | claimed |
| US-20220395481-A1 | BACTERIOSTATIC COMPOSITION, PREPARATION METHOD THEREFOR, AND USE THEREOF | SHENZHEN EULIKAN BIOTECHNOLOGY CO., LTD (CN) | 2022-12-15 | — | — | US | claimed |
| EP-4101437-A1 | BACTERIOSTATIC COMPOSITION, PREPARATION METHOD THEREFOR AND USE THEREOF | Shenzhen Eulikan Biotechnology Co., Ltd. (CN) | 2022-12-14 | — | — | EP | claimed |
| CN-214441134-U | Proestrone capsule dust collecting equipment | 浙江安宝药业有限公司 | 2021-10-22 | — | — | CN | claimed |
| CN-110818758-A | Crystallization process of promestrene crystal | 北京金城泰尔制药有限公司 | 2020-02-21 | — | — | CN | claimed |
| CN-110218234-A | The synthesis technology of Promestriene | 北京金城泰尔制药有限公司 | 2019-09-10 | — | — | CN | claimed |
| CN-107987115-B | Utilize the method for Promestriene organic waste residues recycling estradiol | 北京金城泰尔制药有限公司 | 2019-09-03 | — | — | CN | claimed |
| CN-110003298-A | A kind of synthetic method of Promestriene | 中国人民解放军军事科学院防化研究院 | 2019-07-12 | — | — | CN | claimed |
| EP-3501543-A1 | METHOD FOR MANUFACTURING VAGINAL DRUG DELIVERY SYSTEMS USING A THREE DIMENSIONAL PRINTER | Delim Cosmetics & Pharma S.r.l. (IT) | 2019-06-26 | — | — | EP | claimed |
| US-20030181430-A1 | Novel topical oestroprogestational compositions with a systemic effect | LABORATOIRE THERAMEX (MC) | 2003-09-25 | — | — | US | claimed |
| WO-2003055464-A1 | MICRONIZED PHARMACEUTICAL OR NUTRACEUTICAL POWDER WITH IMMEDIATE RELEASE | BESINS INTERNATIONAL BELGIQUE (BE) | 2003-07-10 | — | — | WO | claimed |
| US-20030124191-A1 | Use of an immediate-release powder in pharmaceutical and nutraceutical compositions | GALENIX INNOVATIONS (FR) | 2003-07-03 | — | — | US | claimed |
| WO-2003043612-A1 | MICRONIZED FILM-FORMING POWDER COMPRISING AN ACTIVE SUBSTANCE | BESINS INTERNATIONAL BELGIQUE (BE) | 2003-05-30 | — | — | WO | claimed |
| US-20030096012-A1 | Film-forming powder, compositions containing it, methods for their preparation and their uses | GALENIX INNOVATIONS (FR) | 2003-05-22 | — | — | US | claimed |
| WO-2003039552-A1 | COMBINATION OF PDE4 OR PDE3/4 INHIBITOR AND AN ANTI-RHEUMATIC DRUG | ALTANA PHARMA AG (DE) | 2003-05-15 | — | — | WO | claimed |
| US-20030092706-A1 | Combination | NYCOMED GMBH (DE) | 2003-05-15 | — | — | US | claimed |
| CN-1407898-A | Novel topical oestroprogestational compositions with systemic effect | THERAMEX (MC) | 2003-04-02 | — | — | CN | claimed |
| EP-1265617-A2 | NOVEL TOPICAL OESTROPROGESTATIONAL COMPOSITIONS WITH SYSTEMIC EFFECT | Laboratoire Theramex SAM (MC) | 2002-12-18 | — | — | EP | claimed |
| WO-2002022132-A2 | NOVEL TOPICAL OESTROPROGESTATIONAL COMPOSITIONS WITH SYSTEMIC EFFECT | LABORATOIRE THERAMEX (MC) | 2002-03-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181430-A1 | Novel topical oestroprogestational compositions with a systemic effect | CYP19A1, PGR, SHBG | ESR1 34/4885MAPT 3009/4885KMT2A 3204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.